By Chris Gardner

Watch MLO’s interview with Diasorin executives discussing the latest challenges and innovations in a shifting respiratory landscape

At this year’s annual meeting of the Association for Diagnostics & Laboratory Medicine, Diasorin team members were interviewed about the trends in respiratory testing by Mark Hagland, contributing editor to Medical Laboratory Observer, better known to readers as MLO.

Two of our respiratory testing experts were interviewed: Michelle Tabb, Chief Scientific Officer, and Giulia Amicarelli, Vice President of Global Molecular Marketing and Marketing Services. Together, they offered terrific insight into the shifting landscape, current challenges, and the latest innovations in respiratory testing.

Watch the quick video to learn more. Featured here are a few of their top insights:

Market changes

The rise of diagnostic stewardship has led to more laboratories aiming to run the right test for the right patient at the right time. Yet making that decision can be incredibly complex for respiratory testing in a post-pandemic world, with varying viruses circulating alongside SARS-CoV-2 depending on the season and population. Therefore, having flexibility in which pathogens to test for based on patient type is key.

Lab challenges

It’s no secret that clinical labs are facing a perfect storm of challenges: rising costs, staff shortages, and increased demand. Diagnostic stewardship approaches help address some of these issues, and many clinical labs are examining the overall pathogen prevalence, platform selection, and algorithm development to make their processes more efficient.

Helpful innovation

To help labs achieve their diagnostic stewardship goals, provide high-quality respiratory testing to patients, and streamline their workflows to ease the burden on staff, Diasorin recently launched its LIAISON PLEX^® System and the LIAISON PLEX^® Respiratory Flex Assay. The system utilizes a new approach that allows users to benefit from syndromic testing while customizing reported targets to prevent unnecessary over testing. This is the first fully customizable syndromic test for respiratory infections, designed to fit within current reimbursement strategies, and enables target selection according to patient needs, using a single workflow and testing platform.

To learn more about respiratory testing (and earn free CE credits!), check out this MLO article on the value of flexibility in respiratory testing.